Earnings ·
Verrica Pharmaceuticals Inc. reported second quarter 2026 financial results, posting total revenue of $5.9 million and…
VRCAVerrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. reported second quarter 2026 financial results, posting total revenue of $5.9 million and a net loss of $13.2 million, or $0.62 per share. U.S. YCANTH product revenue increased 18.7% to $5.1 million, while dispensed applicator units grew 46.1% year-over-year to 19,626. The company recognized a $1.7 million expense for a legal settlement related to class action proceedings. Verrica also announced a new credit facility with an entity controlled by Chairman Paul B. Manning for up to $27.5 million, which management believes could extend the cash runway into 2028. Topline data from the global Phase 3 program for common warts is expected in mid-2027. Verrica Pharmaceuticals Inc. operates in the biotechnology industry, developing and commercializing medications for dermatological diseases.